REGENXBIO Inc. (RGNX)
NASDAQ: RGNX · Real-Time Price · USD
7.85
-0.05 (-0.63%)
Aug 8, 2025, 4:00 PM - Market closed
REGENXBIO Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2016 - 2020 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2016 - 2020 |
Operating Revenue | 155.78 | 83.33 | 90.24 | 112.72 | 470.35 | 154.57 | Upgrade |
| 155.78 | 83.33 | 90.24 | 112.72 | 470.35 | 154.57 | Upgrade | |
Revenue Growth (YoY) | 74.95% | -7.66% | -19.94% | -76.03% | 204.30% | 338.70% | Upgrade |
Cost of Revenue | 36.22 | 33.57 | 37.21 | 54.55 | 233.27 | 202.01 | Upgrade |
Gross Profit | 119.56 | 49.76 | 53.03 | 58.18 | 237.08 | -47.44 | Upgrade |
Selling, General & Admin | 79.7 | 76.62 | 87.79 | 85.28 | 79.33 | 63.82 | Upgrade |
Research & Development | 208.52 | 208.52 | 229.27 | 242.45 | - | - | Upgrade |
Other Operating Expenses | 0.93 | 0.87 | 0.4 | -14.18 | 0.33 | 0.3 | Upgrade |
Operating Expenses | 284.16 | 281.01 | 317.46 | 313.56 | 77.1 | 71.79 | Upgrade |
Operating Income | -164.6 | -231.25 | -264.43 | -255.38 | 159.98 | -119.23 | Upgrade |
Interest Expense | -29.8 | -12.66 | -6.86 | -23.25 | -26.28 | -0.77 | Upgrade |
Interest & Investment Income | 18.83 | 18.9 | 11.34 | 5.73 | 7.54 | 13.99 | Upgrade |
EBT Excluding Unusual Items | -175.57 | -225 | -259.95 | -272.91 | 141.25 | -106.01 | Upgrade |
Merger & Restructuring Charges | - | - | -3.7 | - | - | - | Upgrade |
Asset Writedown | - | -2.1 | - | - | - | - | Upgrade |
Other Unusual Items | - | - | - | -7.5 | - | - | Upgrade |
Pretax Income | -175.57 | -227.1 | -263.65 | -280.41 | 141.25 | -106.01 | Upgrade |
Income Tax Expense | - | - | -0.15 | -0.08 | 13.41 | 5.24 | Upgrade |
Net Income | -175.57 | -227.1 | -263.49 | -280.32 | 127.84 | -111.25 | Upgrade |
Net Income to Common | -175.57 | -227.1 | -263.49 | -280.32 | 127.84 | -111.25 | Upgrade |
Shares Outstanding (Basic) | 51 | 50 | 44 | 43 | 42 | 37 | Upgrade |
Shares Outstanding (Diluted) | 51 | 50 | 44 | 43 | 44 | 37 | Upgrade |
Shares Change (YoY) | 10.99% | 13.21% | 1.35% | -1.73% | 17.79% | 1.61% | Upgrade |
EPS (Basic) | -3.43 | -4.59 | -6.02 | -6.50 | 3.01 | -2.98 | Upgrade |
EPS (Diluted) | -3.43 | -4.59 | -6.02 | -6.50 | 2.91 | -2.98 | Upgrade |
Free Cash Flow | - | -175.56 | -228.37 | -238.21 | 134.7 | -80.93 | Upgrade |
Free Cash Flow Per Share | - | -3.55 | -5.22 | -5.52 | 3.07 | -2.17 | Upgrade |
Gross Margin | 76.75% | 59.72% | 58.76% | 51.61% | 50.41% | -30.69% | Upgrade |
Operating Margin | -105.66% | -277.51% | -293.02% | -226.55% | 34.01% | -77.14% | Upgrade |
Profit Margin | -112.70% | -272.54% | -291.99% | -248.68% | 27.18% | -71.97% | Upgrade |
Free Cash Flow Margin | - | -210.69% | -253.06% | -211.32% | 28.64% | -52.36% | Upgrade |
EBITDA | -148.7 | -215.03 | -247.11 | -242.47 | 169.54 | -110.83 | Upgrade |
EBITDA Margin | -95.46% | -258.05% | -273.83% | -215.10% | 36.05% | -71.70% | Upgrade |
D&A For EBITDA | 15.89 | 16.22 | 17.32 | 12.91 | 9.56 | 8.41 | Upgrade |
EBIT | -164.6 | -231.25 | -264.43 | -255.38 | 159.98 | -119.23 | Upgrade |
EBIT Margin | -105.66% | -277.51% | -293.02% | -226.55% | 34.01% | -77.14% | Upgrade |
Effective Tax Rate | - | - | - | - | 9.49% | - | Upgrade |
Revenue as Reported | 155.78 | 83.33 | 90.24 | 112.72 | 470.35 | 154.57 | Upgrade |
Updated Aug 7, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.